The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Weight Loss Drug Users Are Giving Up Their Vices This new study was prospective, meaning the researchers proactively tracked how people’s alcohol use changed after starting GLP-1 therapy (many ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

The rise of GLP-1 weight loss drugs represents a shift in the way consumers ... The Acosta Group study confirms the growing interest in GLP-1 products and shows how this therapeutic option has ...

The study tested the drug as a monotherapy ... which Lilly said indicates that patients could lose more with continued use of the drug. Like other GLP-1 drugs, the most common adverse effects ...

announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for diabetes and weight loss. The trial of the drug ...

The study, conducted 4,489 of US adults (including 332 currently taking a GLP-1 and 151 no longer on the medication) found that most individuals taking GLP-1s for weight loss do not expect to stay ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...